3 Robinhood Stocks That Warren Buffett Absolutely Loves

This post was originally published on this siteWarren Buffett is about as different from the stereotypical Robinhood investor as you can get. Having just turned 90 years old, he’s very

Read More

Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories?

This post was originally published on this siteOne stock appears to be the clear winner in a matchup between these big coronavirus-focused healthcare companies. Keith Speights. (TMFFishBiz). Aug

Read More

3 Great Dividend Stocks to Buy in September

This post was originally published on this siteAny time is a great time to buy strong dividend stocks. They literally pay you to own them. Over the long run, you can amass tremendous returns by

Read More

How Close Are Aurora Cannabis and Canopy Growth to Turning a Profit?

This post was originally published on this siteAurora Cannabis (NYSE:ACB) and Canopy Growth (NYSE:CGC) have some bragging rights. They’re two of the biggest Canadian cannabis producers.

Read More

Better Coronavirus Stock: BioNTech or Emergent BioSolutions?

This post was originally published on this siteEither company could win the race to develop a COVID-19 vaccine, but one has an easier path to victory. Keith Speights. (TMFFishBiz). Aug 22, 2020

Read More

If You Invested $1000 in Novavax’s IPO, This Is How Much Money You’d Have Now

This post was originally published on this siteNovavax (NASDAQ:NVAX) stock is up around 3,500% so far this year. And that’s after a significant recent decline. Earlier this month, shares of

Read More

COVID-19 Pandemic Wreaks Havoc on Myriad Genetics’ Fiscal Q4 Results

This post was originally published on this siteRotten, no good, horrible, abysmal! Take your pick of adjectives to describe how Myriad Genetics (NASDAQ:MYGN) has performed so far in 2020. Over

Read More

How ResMed Trounced Expectations in Q4

This post was originally published on this siteThere were plenty of questions earlier this year about how the COVID-19 pandemic might impact ResMed (NYSE:RMD). It’s fair to say that most of

Read More

What’s Behind Jazz Pharmaceuticals’ Q2 Revenue and Earnings Beats

This post was originally published on this siteJazz Pharmaceuticals (NASDAQ:JAZZ) hasn’t given investors much good news so far in 2020. The drugmaker’s first-quarter results announced

Read More

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

This post was originally published on this siteGilead Sciences (NASDAQ:GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. But the streak

Read More